FDA OKs Amivantamab as First-Line Lung Cancer Treatment

(MedPage Today) -- The FDA approved amivantamab (Rybrevant) plus combination chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) in patients whose tumors harbor EGFR exon 20 insertion mutations, as determined by an approved...

https://www.medpagetoday.com/hematologyoncology/lungcancer/109001

Source: MedPage Today Public Health - March 4, 2024 Category: American Health Source Type: news